[Extravasation of contrast medium in local intra-arterial fibrinolysis of the carotid territory]

Nervenarzt. 1998 Jun;69(6):490-4. doi: 10.1007/s001150050302.
[Article in German]

Abstract

The safety of fibrinolytic therapy is determined with the incidence of intraparenchymatous hemorrhage. When interpreting CT studies after local intra-arterial fibrinolysis (LIF) in the carotid territory, one must consider that a hyperdense lesion may also be caused by extravasation of contrast material during angiography. In this study we retrospectively analyzed CT scans of 24 patients performed within 24 h after LIF and correlated the results with clinical and angiographic findings before and after therapy. Three of 24 patients (12.5%) showed striatocapsular parenchymal hematomas, 2 patients died and 1 showed marked clinical deterioration. Fifteen of 24 patients (62.5%) showed hyperdense lesions without space-occupying effect within striatocapsular infarctions. In 6 of these patients (25%) these lesions were attributable to an extravasation of contrast medium during angiography. This extravasation required at least partial recanalization of the middle cerebral artery and always occurred within a striatocapsular infarction. The pathogenesis of extravasation of contrast medium during local intra-arterial fibrinolysis is unknown. The identification of these lesions, however, is essential for the assessment of safety of local intra-arterial fibrinolysis.

MeSH terms

  • Adult
  • Angiography, Digital Subtraction
  • Carotid Artery Thrombosis / diagnostic imaging
  • Carotid Artery Thrombosis / drug therapy*
  • Cerebral Angiography*
  • Cerebral Hemorrhage / chemically induced
  • Cerebral Hemorrhage / diagnostic imaging*
  • Cerebral Infarction / diagnostic imaging
  • Cerebral Infarction / drug therapy
  • Corpus Striatum / blood supply
  • Corpus Striatum / diagnostic imaging
  • Extravasation of Diagnostic and Therapeutic Materials / diagnostic imaging*
  • Female
  • Humans
  • Infusions, Intra-Arterial
  • Male
  • Middle Aged
  • Risk Factors
  • Thrombolytic Therapy*
  • Tomography, X-Ray Computed*
  • Urokinase-Type Plasminogen Activator / administration & dosage
  • Urokinase-Type Plasminogen Activator / adverse effects

Substances

  • Urokinase-Type Plasminogen Activator